DXCM stock sentiment todayDexcom Inc
Sentiment verdict
Gossip first, financials second — HOT at 85% confidence.
Last updated · cached analysis, refreshes periodically
DXCM
Dexcom IncA dominant player in the CGM space successfully navigating GLP-1 fears and shifting toward undervalued territory following a Q3 recovery.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for DXCM. Not financial advice.
Price · last 12 months
Gossip
The market is currently 'buying the dip' as the panic over GLP-1 weight-loss drugs (which investors feared would eliminate the need for glucose monitoring) subsides. Recent Q3 earnings beats and the launch of the 'Stelo' over-the-counter sensor are driving a narrative of TAM expansion into the Type 2 and health-conscious markets.
- ·Q3 2024 earnings and revenue beat
- ·Launch of Stelo (OTC wearable) in the U.S.
- ·Analyst upgrades (Raymond James price target to $97)
- ·Receding concerns over GLP-1 drug impact
Financial
Dexcom maintains a high-growth profile with industry-leading gross margins (60%+). While the stock trades at a premium P/E compared to the broader market, it is historically cheap relative to its own 5-year average. Revenue growth remains robust at double digits as penetration in the Type 2 diabetes market accelerates.
- ·20%+ Revenue growth YoY
- ·Free Cash Flow positive and growing
- ·40%+ discount to estimated discounted cash flow (DCF) fair value
- ·Expanding EBITDA margins
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Strong conviction — insiders and patient capital are backing this.
- ·No open-market insider trades in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Intense pricing competition from Abbott's FreeStyle Libre 3
- ·Potential deceleration in U.S. market saturation
- ·High sensitivity to Medicare/Medicaid reimbursement policy changes
Peer temperature
How direct competitors stack up against DXCM right now.
- NEUTRALABTAbbott Laboratories
COLDER — Offers more diversification but lower specific CGM growth upside compared to Dexcom's pure-play focus.
See full analysis → - COLDMDTMedtronic plc
COLDER — Struggling with legacy tech drag and slower innovation cycles in their diabetes division compared to DXCM's G7 momentum.
See full analysis → - HOTPODDInsulet Corporation
HOTTER — Trading at a higher valuation but benefiting from the 'Automated Insulin Delivery' (AID) synergy specifically with Dexcom sensors.
See full analysis →
- DXCM-4.6%
- ABT+7.5%
- MDT+11.9%
- PODD+14.7%
Analyst price target
Consensus average of 21 analysts · median 96.00
Source: StockAnalysis.com · updated 2026-10-30
Recent headlines
- Yahoo Finance UKDexCom (DXCM) Stock Looks Below Fair Value on Cash Flow
- Investor's Business DailyDexcom Shakes Off Abbott-Tied Malaise As U.S. Wearables Market Takes Off
- Zacks Investment ResearchDexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise
- TradingViewDexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise
- Investing.com NigeriaRaymond James raises DexCom stock price target to $97 on U.S. growth
- Simply Wall StDexCom (DXCM) Stock Price Trails Stronger Q3 Earnings Momentum
AI-generated analysis for informational purposes only. Not financial advice.